Pancreatic endocrine carcinoma

MONDO:0005893

An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. The mitotic count is more than 20 per 10 HPF. According to the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm, it is classified either as small or large cell neuroendocrine carcinoma.

Also known as: Pancreatic Neuroendocrine cancer, carcinoma of endocrine pancreas, carcinoma, islet cell, malignant, endocrine pancreas carcinoma, high grade pancreatic neuroendocrine carcinoma, high-grade pancreatic neuroendocrine carcinoma, islet cell cancer, islet cell carcinoma

2919 clinical trials for this condition and its sub-types, 12 tagged with Pancreatic endocrine carcinoma itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Digestive system carcinoma (4898) ↑ Malignant pancreatic neoplasm (1450) ↑ Neuroendocrine carcinoma (744) ↑ Pancreatic neuroendocrine neoplasm (85)

Sub-types of Pancreatic endocrine carcinoma

Pancreatic large cell neuroendocrine carcinoma 0 trials
Pancreatic small cell neuroendocrine carcinoma 0 trials

Including sub-types (2919) Tagged with Pancreatic endocrine carcinoma (12)

Trials to join now! 4 Not yet finished but already full! 6 Completed 1 Terminated 1

Pazopanib dose hunt in frail seniors halted early

Disease control Stopped early

This phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…

Phase 1 • Sponsor: Institut Claudius Regaud • Aim: Disease control

Last updated Jun 27, 2026 12:08 UTC

Pancreatic endocrine carcinoma

Where it sits in the disease tree

Pazopanib dose hunt in frail seniors halted early